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CCAAT/enhancer binding protein alpha (CEBPA) mutations in AML are associated with favourable prognosis and are divided into
N- and C-terminal mutations. The majority of AML patients have both types of mutations. We assessed the prognostic significance
of single (n¼7) and double (n¼12) CEBPA mutations among 224 AML patients. Double CEBPA mutations conferred a
decisively favourable overall (P¼0.006) and disease-free survival (P¼0.013). However, clinical outcome of patients with single
CEBPA mutations was not different from CEBPA wild-type patients. In a multivariable analysis, only double – but not single – CEBPA
mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with
CEBPA mutations.
British Journal of Cancer (2009) 100, 1343–1346. doi:10.1038/sj.bjc.6604977 www.bjcancer.com
Published online 10 March 2009
& 2009 Cancer Research UK
Keywords: prognosis; AML; mutations; CEBPA; risk assessment
                                     
One of the crucial transcription factors for myeloid cell develop-
ment is the CCAAT/enhancer binding protein alpha (CEBPA)
(Rosenbauer and Tenen, 2007). Targeted disruption of CEBPA
results in a selective block of granulocyte maturation (Zhang et al,
1997), whereas conditional expression of CEBPA in precursor cells
is sufficient to trigger granulocytic differentiation (Radomska et al,
1998). In AML patients, deregulation of CEBPA function is a
common event comprising of genomic mutations (Pabst et al,
2001a; Frohling et al, 2004; Nerlov, 2004), transcriptional and post-
transcriptional suppression (Pabst et al, 2001b; Helbling et al,
2004; Helbling et al, 2005), and inactivation by phosphorylation
(Radomska et al, 2006).
Two types of CEBPA mutations are predominantly seen: frame-
shift mutations in the N-terminal truncate the wild-type protein,
whereas formation of a dominant-negative 30-kDa peptide
initiated from an ATG further downstream is not affected. In
contrast, C-terminal CEBPA mutations are in-frame insertions or
deletions, thereby affecting DNA binding and homo- or hetero-
dimerisation with other CEBP family members (Nerlov, 2004). The
majority of AML patients with CEBPA mutations have both types
of mutations, usually on different alleles. However, both types can
occur as single CEBPA mutations.
Earlier study has indicated that CEBPA mutations in cyto-
genetically normal AML patients are associated with favourable
prognosis (Frohling et al, 2004; Bienz et al, 2005; Gaidzik and
Dohner (2008); Marcucci et al, 2008; Schlenk et al, 2008). Here, we
assessed the prognostic significance of the different types of CEBPA
mutations among a cohort of 224 consecutive AML patients of all
subtypes. By direct sequencing, we identified 12 patients with
double and 7 with single heterozygous CEBPA mutations. Patients
with double CEBPA mutations represented the combination of
C- and N-terminal mutation types. We found that favourable
prognosis was exclusively associated with the double CEBPA muta-
tion status, whereas the clinical outcome of patients with single
CEBPA mutations did not differ from CEBPA wild-type patients.
MATERIALS AND METHODS
Patients
Malignant cells were collected at diagnosis from the Ficoll-
separated mononucleated cells of bone marrow aspirates (132
patients) or peripheral blood (92 patients) from consecutive AML
patients seen at the Department of Oncology, University Hospital,
Bern, Switzerland between 2001 and 2007. Informed consent from
all patients was obtained according to the Declaration of Helsinki,
and the studies were approved by decisions of the local ethics
committee of Bern, Switzerland. Patients were uniformly treated
within the HOVON/SAKK 30/00 protocol.
CEBPA mutational analysis
The entire coding region of the CEBPA gene was amplified using
three overlapping PCR primer pairs as described earlier (Bienz
et al, 2005). Sequences of the primers are listed in Supplementary
Table S1. PCR products were sequenced in both directions.
Abnormal sequencing results were repeated twice in both
directions, including repetitions of PCR.
Received 13 November 2008; revised 17 February 2009; accepted 18
February 2009; published online 10 March 2009
*Correspondence: Professor T Pabst; E-mail: thomas.pabst@insel.ch
British Journal of Cancer (2009) 100, 1343–1346
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sReporter gene assays
H1299 cells were transfected with 80ng of luciferase plasmid
encoding an oligomeric CEBPA site, together with 20ng of
pcDNA3-CEBPA or empty pcDNA3 vector along with 1.0ng of
CMV-Renilla plasmid. After 24h, luciferase activities were
determined (Pabst et al, 2001a). Each transfection experiment
was repeated at least three times.
Protein isolation and western blot analyses: Fifty micrograms of
extracted proteins from whole-cell lysates were analysed with a
rabbit polyclonal antibody against CEBPA (1:1000; Santa Cruz
Biotechnology, Santa Cruz, CA, USA.; sc-61).
Statistical Analysis
Patients alive without progression or relapse by the time of
analysis were censored at the time of their last follow-up. Time-to-
event curves were constructed according to the Kaplan–Meier
method and were compared with the log-rank w
2-test.
RESULTS AND DISCUSSION
By sequencing the entire coding region, we identified 19 patients
with CEBPA mutations in our cohort of 224 AML patients at
diagnosis. Of these 12 patients had the combination of the N- and
the C-terminal type of mutation, further referred here as double
CEBPA mutation, and 7 patients had a single CEBPA mutation.
Patients with the in-frame insertion polymorphism in the second
transactivation domain (Wouters et al, 2007), with base pair
variation(s) that did not lead to amino acid changes, or with in-
frame sequence variations of unknown significance (one patient),
were not considered in the further analysis. All CEBPA mutations
are presented in detail in Supplementary Tables S2A and S2B. Two
patients with a single point mutation encoding a novel stop codon
located downstream of the alternative ATG at position 120 were
not of the classic N-terminal mutation type, as formation of the
30-kDa peptide was also affected, but they were classified as
having single CEBPA mutations because of the functional
relevance of these particular mutations.
We identified CEBPA mutations exclusively in patients below
the age of 61 years at diagnosis. Thus, only AML patients in this
age range were studied in the control group of CEBPA wild-type
patients, allowing comparison of patients treated within the
same protocol. We detected no differences between patients with
single and double CEBPA mutations with regard to FAB subtypes,
leucocytes at diagnosis, percentage of peripheral blasts at
diagnosis, bone marrow infiltration at diagnosis, and LDH levels
(Supplementary Table S3).
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Figure 1 (A) Overall survival of AML patients without CEBPA mutations (wt; n¼205), with a single (n¼7), and with the combination of C- and
N-terminal CEBPA mutations (double; n¼12). Patients who are alive were censored at the last follow-up. X-axis indicates months, Y-axis is probability of
survival. (B) Disease-free survival of AML patients without (wt; n¼205)), with a single (n¼7), or with double (n¼12) CEBPA mutations. (C) Transient
transfection experiments in H1299 cells using equal amounts of pcDNA3 expression plasmids encoding human CEBPA wild-type (wt), the N-terminal frame-
shift mutation 245delC (as present in patient #3s in Supplementary Table S2), the C-terminal in-frame mutation 1079–1080insTCT (as present in patient
#5s), and the combination of both plasmids. V: pcDNA3 expression plasmid alone. The luciferase reporter construct encodes an oligomeric CEBPA binding
site. (D) Western blot analyses for CEBPA protein using whole-cell lysates of patients #27 (AML-M1 with a normal karyotype and no abnormalities in
CEBPA, FLT3, and NPM1), #3s (AML-M2 with the N-terminal frame-shift mutation 245delC), #11d (AML-M1 with both the N-terminal 213insAG and the
C-terminal 1088-1089insCCG mutations), and #5s (AML-M1 with the C-terminal in-frame mutation 1079–1080insTCT). (E) Schematic presentation of
CEBPA wild-type protein (upper panel) and the 30-kDa peptide initiated at the ATG at amino acid 120 (lower panel). Black bars indicate the two
transactivation domains, and grey bars represent the region for DNA binding and homo-/heterodimerisation.
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sively detected in the single CEBPA mutation group, including one
patient with FLT3-ITD and one with NPM1 mutation. All patients
with CEBPA mutations had a normal karyotype with the exception
of one patient with monosomy 7 in the single CEBPA mutation
group and one with del6q24 in the double CEBPA mutation group.
Results of karyotype and molecular analyses are given in
Supplementary Table S4.
Comparing patients with single vs double CEBPA mutations, we
found that the clinical outcome differed markedly (Supplementary
Table S5). A complete remission after induction chemotherapy was
achieved in all the 19 AML patients with CEBPA mutations.
However, patients with single CEBPA mutations had a significantly
worse median overall survival (OS) of 15 months (Figure 1A;
P¼0.006) and disease-free survival (DFS) of 12 months (Figure 1B;
P¼0.013) compared with patients with double CEBPA mutations
in whom both median DFS and OS were not reached after a median
follow-up of 34 months. Moreover, the course of the disease of
patients with single CEBPA mutations was not different both for
OS and DFS from CEBPA wild-type patients. Finally, in a
multivariable analysis discriminating white blood cell count, age,
NPM1 mutations, and FLT3-ITD, only double CEBPA mutations,
but not single CEBPA mutations, were identified as independent
prognostic factors (Table 1). The CEBPA mutation status per se
turned out to be of independent prognostic significance.
To illustrate the consequences of single vs double CEBPA
mutations in terms of CEBPA function, we transfected H1299 cells
with expression plasmids encoding CEBPA wild-type, an N-terminal
frame-shift mutation, a C-terminal in-frame mutation, or the
combination of both plasmids, and we determined the potential of
these CEBPA peptides to activate a target promoter sequence as
present in the G-CSF receptor promoter. As illustrated in Figure 1C,
both the N- and the C-terminal CEBPA mutant peptides inhibited
wild-type CEBPA protein in a dominant-negative manner, by
reducing its activation potential by roughly 70%. However, it is
important that the combination of both mutant constructs – in the
absence of wild-type protein – failed to activate at all. This suggests
that CEBPA activity is completely abolished in malignant cells of
patients with double CEBPA mutations, whereas it is retained to
some degree in patients with single CEBPA mutations. In addition,
Figure 1D presents the various CEBPA peptides made in malignant
cells from AML patients with different types of CEBPA mutations. It
indicates that N-terminal frame-shift CEBPA mutations, in fact,
decisively decrease the amount of wild-type CEBPA protein, whereas
the 30-kDa peptide is detectable at a higher amount.
In conclusion, our findings indicate that there is relevant
prognostic heterogeneity within AML patients with CEBPA
mutations. Double CEBPA mutations are associated with distinctly
favourable prognosis, whereas clinical outcome of AML patients
with single CEBPA mutations is not different from CEBPA wild-
type patients. However, the number of patients with a single
CEBPA mutation is limited in our collection of patients, and larger
series are needed to definitively assess its prognostic significance.
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